Exploratory Study of the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
Mayo Clinic
Summary
The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Individuals on an unrestricted regular diet with no dietary restrictions (vegan, low FODMAP, gluten free, dairy-free etc) or other fad diets (e.g., keto, intermittent fasting, etc.). * Healthy subjects will be screened for current or chronic GI symptoms using a 16-item questionnaire. * Only those with an absence of symptoms will eligible to participate. Exclusion Criteria: * For healthy volunteers, will include prior surgery altering the esophagus, stomach, and intestine (except appendectomy). * Chronic daily use of medications affecting GI secretion or motor function.…
Interventions
- DrugOmeprazole
40 MG oral capsules daily
- Dietary SupplementLactobacillus rhamnosus GG
Given as Culturelle Digestive Probiotic in the form of oral capsules daily
- DrugPlacebo
Oral capsules daily that look exactly like the study drug, but contains to active ingredient
Location
- Mayo Clinic ArizonaScottsdale, Arizona